KATHERINE SOLAKLI: Open Payments
NPI 1386913556 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,716 in 52 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $703 · 2025 $1,716
Food & beverage: $1,716
| Company | Payments | Amount |
|---|---|---|
| United Therapeutics Corporation | 17 | $725 |
| Paratek Pharmaceuticals, Inc. | 3 | $166 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $132 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $130 |
| Actelion Pharmaceuticals US, Inc. | 4 | $112 |
| Merck Sharp & Dohme LLC | 1 | $110 |
| ABBVIE INC. | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $80 |
| Melinta Therapeutics, LLC | 3 | $53 |
| Astellas Pharma US Inc | 1 | $32 |
Products named: Remodulin, Orenitram, NUZYRA, Adempas, UPTRAVI, Tyvaso, OFEV, LIVTENCITY.
Industry payments across DC — which companies pay providers there.
